Advanced NSCLC with PD-L1 expression on TC and IC has shown higher sensitivity to the PD-L1 inhibitor atezolizumab. This study is to examine the association between PD-L1 expression on TC and IC and clinicopathological characteristics, EGFR/ALK driver oncogenes status and prognosis in surgically resected NSCLC.
We analyzed 514 NSCLC pts who underwent surgical resection from November 2005 to March 2011 at the National Cancer Center Hospital East. The PD-L1 expression on TC (4 levels of expression: TC0-3) and IC (IC0-3) was evaluated using the Ventana PD-L1 (SP142) antibody IHC assay as recently described (Lancet. 2016; 387: 1837-46). TC1-3 and IC1-3 were defined as positive, respectively.
Median age at tumor resection was 68 (range 30-93) years; male/female 63/37%; smoker/non-smoker 69/31%; squamous cell carcinoma (Sq)/non-Sq 13/87%; EGFR mutations (mut) +/- 26/74%; ALK fusion +/- 3/97%; p-stage I/II/III/IV 60/19/19/2%. PD-L1 expression was as follows; TC0/1/2/3: 81/7/9/4%, IC0/1/2/3: 38/34/22/6%. PD-L1 expression on TC was observed in 19% of tumors, and on IC in 62% of specimens. PD-L1 expression on TC or IC (i.e. TC1-3 or IC1-3) was observed in 63%. Smoking and p-stage II-IV were associated with PD-L1 expression on both TC and IC (P
Smoking and advanced p-stage were associated with PD-L1 expression on both TC and IC while Sq was associated with PD-L1 expression on IC and EGFR mut (-) on TC. PD-L1 expression on TC and IC was not independent prognostic factor.
Clinical trial identification
Legal entity responsible for the study
National Cancer Center Hospital East
Chugai Pharmaceutical Co., Ltd.
S. Nomura: Mr. Nomura received personal fees from Japan Breast Cancer Research Group (JBCRG), and grants from Japan Agency for Medical Research and Development (AMED), outside the submitted work. S. Matsumoto: I reports grants from Chugai, MSD.,Astra Zeneka, Taiho,Ono, Eisai, Pfizer, Kyowa Hakko Kirin, Eli Lilly, Takeda, Novartis, DAIICHI SANKYO, Astellas, and Amgen Astellas. BioPharma, and personal fees from Novartis Pharma K.K., outside the submitted work. K. Yoh: Honoraria: Chugai.
S. Niho: I received grants from Pfizer, Eli Lilly, and AstraZeneca, and honoraria from AstraZeneca, Eli Lilly, Taiho, Boehringer Ingelheim, and Chugai. M. Tsuboi: Honoraria: AstraZeneca,Eli Lilly Japan,Boehringer-Ingelheim Japan,Daiichi-Sankyo,Chugai, Taiho,Johnson & Johnson Japan,Covidien Japan,Teijin,CSL Behring Japan. Research grants outside the submitted work: AstraZeneca. M. Kowanetz: Employee of Genentech + Genentech stock + Genentech patents, or other IP. Patent biomarkers and methods of treating PD-1 AND PD-L1 related conditions pending. M. Sakai, J. Itabashi, R. Shiokawa, A. Morioka, M. Ueda: Employee of Chugai Pharmaceutical Co., Ltd
Y. Kamihara: Employee of Chugai Pharmaceutical Co., Ltd. K. Goto: This study: Chugai Outside the submitted work: MSD, AstraZeneka, Taiho, Nippon Boehringer Ingelheim, Ono, Quintiles, GSK, OxOnc, Pfizer, Kyowa Hakko Kirin, Eli Lilly Japan, Yakult, Sumitomo Dainippon, Takeda, Novartis, Daiichi Sankyo, Astellas, Eisai, Amgen Astellas, BMS. All other authors have declared no conflicts of interest.